Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.

"bifurcation lesions with dual stent implantation and unprotected left main lesions were not allowed (see a list of the full angiographic inclusion and exclusion criteria in data s1 ).; data s1 tables s1-s3"

"Disclosures Dr Johnson has received honoraria from Abbott Vascular, AstraZeneca, Boston Scientific, Medtronic, and Terumo. Dr Baumbach has received institutional research support from Abbott Vascular and honoraria from AstraZeneca, Sinomed, Microport, Abbott Vascular, Cardinal Health, and KSH. Dr Ben‐Yehuda and Ms Issever are employee of the Cardiovascular Research Foundation, which received funding from Medinol Ltd for the conduct of the trial. The remaining authors have no disclosures to report."

"Sources of Funding The study was funded by Medinol Ltd, and the study protocol was developed by the lead investigators and the sponsor."

"Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03877848."